Essential Genes Analysis Reveals Small Ribosomal Subunit Protein ES28 May Be a Prognostic Factor and Potential Vulnerability in Osteosarcoma

Overview

Journal J Bone Oncol

Publisher Elsevier

Date 2024 Jan 11

PMID 38204480

Authors

Chao Liang

Juan Zhou

Yongjie Wang

Yin Sun

Jin Zhou

Lan Shao

Zhichang Zhang

Wangjun Yan

Zhiyan Liu

Yang Dong

Affiliations

Soon will be listed here.

Abstract

Background: Osteosarcoma, the most common primary malignant bone tumor, is currently treated with surgery combined with chemotherapy, but the limited availability of targeted drugs contributes to a poor prognosis. Identifying effective therapeutic targets is crucial for improving the prognosis of osteosarcoma patients.

Methods: We screened the DepMap database to identify essential genes as potential therapeutic targets for osteosarcoma. Gene Set Enrichment Analysis (GSEA) was employed to elucidate the biological roles of these essential genes. Promising candidates were filtered through univariate and multivariate Cox analyses, as well as Kaplan-Meier survival analyses using the GSE21257-OSA and TARGET-OSA datasets. The functional role of the target gene was assessed through cell experiments. Additionally, an in situ nude mice model was established to observe the gene's function, and RNA sequencing was utilized to explore the underlying molecular mechanism.

Results: A total of 934 essential genes were identified based on their effects (Chronos) using the DepMap database. These genes were primarily enriched in the ribosome pathway according to GSEA analysis. Among them, 195 genes were associated with the ribosome pathway. , , and were validated as promising candidates following univariate and multivariate Cox analyses of the TARGET-OSA and GSE21257-OSA datasets. Kaplan-Meier survival analyses indicated represented an especially promising target, with high expression correlating with poor prognosis. Knockdown of small ribosomal subunit protein eS28, the protein of , inhibited proliferation, migration, and invasion in both in and in experiments. Silencing affected the MAPK signaling pathway in osteosarcoma.

Conclusion: In summary, has been identified as an essential gene for osteosarcoma cell survival and eS28 may serve as a potential vulnerability in osteosarcoma.

Citing Articles

The Interplay Between the Oncogene and Ribosomal Proteins in Osteosarcoma Onset and Progression: Potential Mechanisms and Indication of Candidate Therapeutic Targets.

Guerrieri A, Hattinger C, Marchesini F, Melloni M, Serra M, Ibrahim T Int J Mol Sci. 2024; 25(22).

PMID: 39596100 PMC: 11593864. DOI: 10.3390/ijms252212031.

Development and experimental validation of hypoxia-related gene signatures for osteosarcoma diagnosis and prognosis based on WGCNA and machine learning.

Wen B, Chen J, Ding T, Mao Z, Jin R, Wang Y Sci Rep. 2024; 14(1):18734.

PMID: 39134603 PMC: 11319349. DOI: 10.1038/s41598-024-69638-3.

References

Zhang J, Li Y, Liu H, Zhang J, Wang J, Xia J . Genome-wide CRISPR/Cas9 library screen identifies PCMT1 as a critical driver of ovarian cancer metastasis. J Exp Clin Cancer Res. 2022; 41(1):24. PMC: 8760697. DOI: 10.1186/s13046-022-02242-3. View

Dempster J, Boyle I, Vazquez F, Root D, Boehm J, Hahn W . Chronos: a cell population dynamics model of CRISPR experiments that improves inference of gene fitness effects. Genome Biol. 2021; 22(1):343. PMC: 8686573. DOI: 10.1186/s13059-021-02540-7. View

Ritter J, Bielack S . Osteosarcoma. Ann Oncol. 2010; 21 Suppl 7:vii320-5. DOI: 10.1093/annonc/mdq276. View

Kang J, Brajanovski N, Chan K, Xuan J, Pearson R, Sanij E . Ribosomal proteins and human diseases: molecular mechanisms and targeted therapy. Signal Transduct Target Ther. 2021; 6(1):323. PMC: 8405630. DOI: 10.1038/s41392-021-00728-8. View

Feng X, Tang M, Dede M, Su D, Pei G, Jiang D . Genome-wide CRISPR screens using isogenic cells reveal vulnerabilities conferred by loss of tumor suppressors. Sci Adv. 2022; 8(19):eabm6638. PMC: 9106303. DOI: 10.1126/sciadv.abm6638. View

Meltzer P, Helman L . New Horizons in the Treatment of Osteosarcoma. N Engl J Med. 2021; 385(22):2066-2076. DOI: 10.1056/NEJMra2103423. View

Hosseini S, Salehifard Jouneghani A, Ghatrehsamani M, Yaghoobi H, Elahian F, Mirzaei S . CRISPR/Cas9 as precision and high-throughput genetic engineering tools in gastrointestinal cancer research and therapy. Int J Biol Macromol. 2022; 223(Pt A):732-754. DOI: 10.1016/j.ijbiomac.2022.11.018. View

Balon K, Sheriff A, Jackow J, Laczmanski L . Targeting Cancer with CRISPR/Cas9-Based Therapy. Int J Mol Sci. 2022; 23(1). PMC: 8745084. DOI: 10.3390/ijms23010573. View

Huang Z, Lan T, Wang J, Chen Z, Zhang X . Identification and validation of seven RNA binding protein genes as a prognostic signature in oral cavity squamous cell carcinoma. Bioengineered. 2021; 12(1):7248-7262. PMC: 8806873. DOI: 10.1080/21655979.2021.1974328. View

10.

Chan Y, Lu Y, Wu J, Zhang C, Tan H, Bian Z . CRISPR-Cas9 library screening approach for anti-cancer drug discovery: overview and perspectives. Theranostics. 2022; 12(7):3329-3344. PMC: 9065202. DOI: 10.7150/thno.71144. View

11.

Hu Z, Wen S, Huo Z, Wang Q, Zhao J, Wang Z . Current Status and Prospects of Targeted Therapy for Osteosarcoma. Cells. 2022; 11(21). PMC: 9653755. DOI: 10.3390/cells11213507. View

12.

Kurata M, Yamamoto K, Moriarity B, Kitagawa M, Largaespada D . CRISPR/Cas9 library screening for drug target discovery. J Hum Genet. 2017; 63(2):179-186. DOI: 10.1038/s10038-017-0376-9. View

13.

Elhamamsy A, Metge B, AlSheikh H, Shevde L, Samant R . Ribosome Biogenesis: A Central Player in Cancer Metastasis and Therapeutic Resistance. Cancer Res. 2022; 82(13):2344-2353. PMC: 9256764. DOI: 10.1158/0008-5472.CAN-21-4087. View

14.

Yau C, Esserman L, Moore D, Waldman F, Sninsky J, Benz C . A multigene predictor of metastatic outcome in early stage hormone receptor-negative and triple-negative breast cancer. Breast Cancer Res. 2010; 12(5):R85. PMC: 3096978. DOI: 10.1186/bcr2753. View

15.

Xu X, Xiong X, Sun Y . The role of ribosomal proteins in the regulation of cell proliferation, tumorigenesis, and genomic integrity. Sci China Life Sci. 2016; 59(7):656-72. DOI: 10.1007/s11427-016-0018-0. View

16.

Yi Y, You K, Park J, Lee S, Seong Y . Ribosomal Protein S6: A Potential Therapeutic Target against Cancer?. Int J Mol Sci. 2022; 23(1). PMC: 8744729. DOI: 10.3390/ijms23010048. View

17.

Chen M, Mao A, Xu M, Weng Q, Mao J, Ji J . CRISPR-Cas9 for cancer therapy: Opportunities and challenges. Cancer Lett. 2019; 447:48-55. DOI: 10.1016/j.canlet.2019.01.017. View

18.

Hide T, Shibahara I, Inukai M, Shigeeda R, Shirakawa Y, Jono H . Ribosomal proteins induce stem cell-like characteristics in glioma cells as an "extra-ribosomal function". Brain Tumor Pathol. 2022; 39(2):51-56. DOI: 10.1007/s10014-022-00434-5. View

19.

Zingg D, Bhin J, Yemelyanenko J, Kas S, Rolfs F, Lutz C . Truncated FGFR2 is a clinically actionable oncogene in multiple cancers. Nature. 2022; 608(7923):609-617. PMC: 9436779. DOI: 10.1038/s41586-022-05066-5. View

20.

Zeng Z, Zhang X, Jiang C, Zhang Y, Wu X, Li J . Identifying novel therapeutic targets in gastric cancer using genome-wide CRISPR-Cas9 screening. Oncogene. 2022; 41(14):2069-2078. DOI: 10.1038/s41388-022-02177-1. View